Track topics on Twitter Track topics that are important to you
Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.
The 'Global and Chinese Sunitinib base Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Sunitinib base industry with a focus on the Chi...
Sunitinib Malate Market: By Disease Pancreatic Neuroendocrine Tumors Kidney Cancer By Region Europe, North America, AsiaPacific Rest of the World RoWForecast 20162021 [Updated: 13092016] Prices from USD $5250
Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a smallmolecule medicine which has to be administered orally and has been proven to be effective in blocki...
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination wi...
Life Sciences Jobs ...
Coadministration of diclofenac and sunitinib, tyrosine kinase inhibitor, led to sex-divergent pharmacokinetic drug-drug interaction outcomes. Male and female mice were administered 60 mg/kg PO suniti...
The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial an...
Two studies presented at the European Society for Medical Oncology 2016 Congress evaluated sunitinib in patients with renal cell carcinomas. The first found that the drug prevents recurrence in patien...
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. In advanced setting and after progression to imatinib, the multi-targeted receptor tyrosine ki...
Sunitinib drug eluting beads (DEB) are a novel anti-angiogenic bead preparation for use in transarterial chemoembolization. However, systematic studies of sunitinib DEB's effect on cancer cells have n...